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Background. End-stage liver disease due to hepatitis 
C virus (HCV) is the most common indication for liver 
transplantation in U.S. veterans. We investigated the 
influence of HCV genotypes on the incidence and tim-
ing of recurrent HCV hepatitis, survival, infectious 
morbidity, and response to interferon-a therapy in 
this unique patient population. 
Methods. HCV genotype was determined by direct 
sequencing of the NS5 region of HCV with type-spe-
cific primers. 
Results. Genotype 1a (66%, 32147) was the predomi-
nant genotype. Type 1b was found in 25% (12/47) of 
patients and type 2b was found in 90/0 (4147). His-
topathologically recurrent HCV hepatitis developed in 
53% (25/47) of the patients after transplantation. This 
group included 45% (14131) of the patients with type 
la, 67% EU~1OF of the patients with type 1b, and 25% (114) 
of the patients with type 2b (P>O.5). The time to recur-
rence and the severity of HCV recurrence as defined 
by aminotransferase levels or Knodell scores were not 
different among the three genotypes. There was a 
trend toward a higher incidence of major infections in 
patients with type 1b (75%) versus type 1a (48%) and 
type 2b (50%) (P=O.l1). The response to interferon-a 
therapy did not differ significantly among the geno-
tYpes. Mortality at 5 years was 16% (5/31) in patients 
WIth genotype la, 42% (5112) in patients with genotype 
1b, and 50% (214) in patients with genotype 2b (P=0.06). 
Conclusions. The incidence, time to recurrence, and 
response to interferon-a therapy did not differ be-
tw~e~ the various genotypes in our liver transplant 
~eclpf~ntsK eow~v~rI there was a trend toward higher 
m.fectlOus morbIdIty and overall mortality in patients 
WIth genotype 1b after transplantation. 
End-stage liver disease due to hepatitis C virus (HCV*) has 
emerged as one of the leading indications for orthotopic liver 
transplantation u-·n Persistent posttransplant viremia has 
been documented in up to 95% of recipients, and histopatho-
logic recurrence has been observed in 30- 70% of patients 
with HCV within the first year after transplantation U-4). 
The precise reason for the disparity between the near uni-
versal recurrence of HCV infection and clinical <histopatho-
logic) recurrence is not known, although the intensity of 
I Address correspondence to: Nina Singh, MD. Infectious Diseases 
Section. Veterans Affairs Medical Center, University Drive C, Pitts-
burgh. PA 152·W. 
• AbbreVlations: ALT, alanine aminotransferase: AST, aspartate 
aminotransferase: c~rvI cytomegalovirus: HeV, hepatitis C virus. 
" 
posttransplant immunosuppression, donor-recipient HLA 
matching, level of pre- and posttransplant viremia, and viral 
genotype have been proposed as contributory variables (5- J 
11). 
Simmonds et a1. (12) have identified 6 major HCV geno-
types and 11 subtypes based upon the phylogenetic analysis 
ofthe NS5 region of the HCV genome. The prevalence of He v 
genotypes shows significant geographic variation (13). In the 
United States and Western Europe, genotypes 1a and 1b are 
common, whereas subtypes 2a, 2b, and 3a occur infrequently. 
In Southeast Asia, genotypes 1b, 2a, and 2b are common, • 
whereas infection with type la is rare. 
Prognostic implications for HCV genotypes in liver trans-
plant recipients have thus far been assessed in only two 
reports published from Europe (5, 7). Both studies demon-
strated that genotype Ib was the most prevalent genotype, 
and infection with genotype Ib was associated with more 
aggressive posttransplant HCV recurrence. An association 
between genotypes and severity of post transplant recurrence 
was not observed in a U.S. study published in abstract form 
(6). To our knowledge, no other study has assessed the asso-
ciation between HCV genotypes and outcome in U.S. patients 
undergoing liver transplantation. 
HCV genotypes have been shown to be variably responsive 
to interferon-a therapy for HCV hepatitis. In the nontrans-
plant setting, genotype Ib has been associated with poor 
response to interferon-a therapy (14-22). In contrast, pa-
tients infected with type 2 have demonstrated a better re-
sponse to interferon-a. An association between response to 
interferon-a and HCV genotypes has never been assessed in 
liver transplant recipients. 
A higher incidence of infections, particularly due to patho-
gens associated with depressed cell-mediated immunity, has 
been demonstrated in patients with recurrent HCV hepatitis 
after liver transplantation (23), However, the effect of dis-
tinct viral genotypes on the incidence and the types of infec-
tions after transplantation is not known. 
End-stage liver disease due to HCV has been documented 
in 53% of U.S. veterans undergoing liver transplantation at 
the Pittsburgh Veterans Affairs Medical Center; recurrent 
HCV hepatitis has developed in 42% of these patients. In this 
study, we assessed the impact ofHCV genotypes on incidence 
and severity of recurrent HCV hepatitis. incidence of infec-
tions, response to interferon-a, and outcome in U.S. veterans 
undergoing liver transplantation. 
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METHODS 
Study population. Between October 1989 and October 1995, 140 
orthotopic liver transplantations were perfonned in 130 consecutive 
U.S. veterans under primary tacrolimus (Prograf, Fujisawa USA, 
Inc., Deerfield, IL)-based immunosuppression. Fifty-three percent 
(68/130) of the patients underwent transplantation for HCV. All of 
these patients were male with a mean age of 46 years (range, 31-63 
years). A history of ethanol use was present in 43% (29/68) of the 
patients with HCV. The diagnosis of HCV infection was established 
by the presence of anti-HCV antibody (EIA-I was used before March 
1992 and EIA-II thereafter) and confinned by a RIBA-II assay. 
Beginning in April 1990, a preoperative serum sample was collected 
and frozen at -80°C in all patients. Recurrent hepatitis was diag-
nosed histopathologically using previously reported criteria and re-
quired the presence of portal lymphoid follicles, mononuclear lobular 
infiltrate, and hepatocyte necrosis with degeneration and ballooning 
in the absence of cytomegalovirus (CMV), herpes simplex virus, 
hepatitis B virus, and rejection (8,24). Patients were followed until 
death or for a median period of 38 months (range, 6-74 months). 
Of68 liver transplant recipients with HCV, a preoperative serum 
sample was unavailable for genotyping in 10 patients and HCV was 
not typeable in 11. Therefore, genotype analysis was available in 47 
patients, who comprised the study population. All donors except one 
were seronegative for HCV. Data on demographics, service in South-
east Asia, timing ofposttransplant HCV recurrence, severity ofHCV 
recurrence (Knodell scores), incidence of major bacterial infections, 
fungal infections, CMV infection and CMV disease, receipt of inter-
feron-a, duration of interferon-a therapy, mortality, and cause of 
death were assessed in all patients. 
Immunosuppression. All patients received tacrolimus and low-
dose prednisone as immunosuppressive agents. One gram of meth-
ylprednisolone was given immediately after revascularization of the 
graft. Twenty milligrams of methylprednisolone were given intrave-
nously daily until the oral route was established, at which time 20 
mg of prednisone were administered daily. During the subsequent 
months, prednisone was slowly tapered. Rejection episodes were 
treated with 1 g of methylprednisolone bolus with or without steroid 
cycles (methylprednisolone given intravenously in four divided doses 
daily, with tapering of the dose from 200 mg to 20 mg a day over 6 
days). OKT3 was used for steroid-resistant rejection. 
Infectious morbidity. Infections were defined as reported previ-
ously (25). Infections were characterized as either major or minor. 
Major infections included bacteremia, intra-abdominal abscess, peri-
tonitis, wound infection, pneumonia, Clostridium difficile colitis, 
cholangitis. invasive fungal infection, and symptomatic CMV infec-
tion (CMV disease). Minor infections included mucocutaneous her-
pes simplex or zoster infections, cystitis, and asymptomatic CMV 
shedding. 
Interferon. a therapy. Response to interferon-a was assessed using 
criteria that have been previously used in liver transplant recipients. 
Complete response was defined as normalization of both aspartate 
aminotransferase (AST) and alanine aminotransferase (AL T). Pa-
tients with any abnonnality of either AST. ALT, or both were con-
sidered nonresponders. Quantitative HCV R.,."lA levels were not 
available for all patients during the interferon-a treatment interval. 
"- Early responders were defined as patients demonstrating complete 
response by 6 months of therapy. Late responders were those who 
did not demonstrate a response at 6 months but responded with 
normalization of AST and ALT after 6 months of therapy. Nonre-
8ponders were patients who did not respond at either 6 months or at 
latest follow-up. 
. Hev genotyplng assay. HCV was extracted from sera by the mod· 
ified guanidinium thiocyanate-phenollchlorofonn technique using a 
.. ' ?>llllllercialiv available kit (R."lAzol B. Biotecx Laboratories. Hous-
ton, TXl. qh~ HCV RNA was then reverse-transcribed into cDNA and 
IlInplified by polymerase chain reaction as described previously; ap-
proPriate measures were taken to prevent polymerase chain reaction 
product contamination (26). Oligonucleotides specific for the NS5 
region of the HCV genome were used as primers: 5' GGCGGAAT-
TCCTGGTCATAGCCTCCGTGAA 3' and 5' TGGGGATCCGTAT-
GATACCCGCTGTTTGA 3'. Polymerase chain reaction-positive 
samples were sequenced directly by the Sanger dideoxynucleotide 
termination method and a modified T7 DNA polymerase (Sequenase 
version 2.0 kit; United States Biochemical Corp., Cleveland, OH) 
using internal primers published by Simmonds et al. (27). For some 
reactions, the external primers were used for sequencing. Altogether, 
a 22-basepair fragment of the NS5 region was read and used for 
comparison, as described by Simmonds et al. (27). Of 47 samples, 22 
were genotyped using the type-specific primers for the C region (28). 
Statistical analysis. Demographics and genotyping were entered 
into a database (PROPHET Statistics, BBN Systems and Technolo-
gies, Cambridge, MA). Patients were compared as follows: continu-
ous variables (episodes of infection, rejection, etc.) were compared 
using the t test or, when a normal distribution could not be assumed, 
the Mann-Whitney test. Categorical data (presence or absence of 
CMV, residence in Southeast Asia, etc.) were compared using the 
chi-square or Fisher's exact test. A three-way comparison of age was 
done using the analysis of variance test. A Kaplan-Meier probability 
curve was_constructed using the date of HCV recurrence as the end 
point. The Mantel-Cox test was used to compare probability curves. 
RESULTS 
Of 47 liver transplant recipients with HeV, 66% (3V47) 
had genotype la, 25% (12/47) had genotype lb, and 9% (4147) 
had genotype 2b (Table 1). The median age of the patients 
with genotype la or lb was 45 years and that of patients with 
type 2b was 55 years; patients with genotype 2b were signif-
icantly older than other patients (P=O.Ol) (Table 1). Forty-
five percent (14131) of the patients with genotype la, 58% 
(7/12) of patients with type 1b, and 25% (V4) with type 2b 
(P>O.5) had served and resided in Southeast Asia during the 
Vietnam War. 
Histopathologically recurrent HeV hepatitis after trans-
plantation developed in 53% (25/47) of the patients. The 
recurrence rate was 52% (16131) in patients with genotype 
la, 67% (8/12) in patients with type lb, and 25% (V4) in 
patients with type 2b (P>0.5). Figure 1 depicts the Kaplan-
Meier probability of recurrent HeV hepatitis in the three 
genotypes. The median time to recurrence after transplanta-
tion was 301 days (range, 87-994 days) for type la, 198 days 
(range, 72-714 days) for type lb, and 111 days for type 2b 
(Table 2); the time to recurrence did not differ significantly 
among the HeV genotypes (P=O.5). Severity of HeV recur-
rence, as assessed by aminotransferase levels and Knodell 
scores at the onset of recurrent HeV hepatitis, was not dif-
ferent for the three genotypes (Table 2). Incidence of rejection 
and intensity of immunosuppression, as assessed by the 
number of corticosteroid boluses and recycles received, before 
recurrent HeV hepatitis did not differ between patients with 
genotype 1a or Ib who developed recurrence. None of the 
study patients received OKT3 (Table 1). 
Response to interferon-a. The response to interferon-a was 
assessable in 18/25 patients with HeV recurrence who re-
ceived >6 months of interferon-a treatment (4 patients re-
ceived < 1 month of -ainterferon before they died, 2 patients 
did not receive interferon-a because of contraindications, and 
1 patient started interferon-a therapy only 1 month ago). At 
6 months, 25% (3/12) of patients with genotype la and 17% 
(1/6) of patients with type 1b were biochemical responders 
(P>O.2l. Six of the nine nonresponders with type la and four 
of six nonresponders with type Ib continued interferon-a 
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TABLE 1. Demographic and clinical variable in patients with the three Hey genotypes 
~----------------
Variable 
Prevalence in patients with 
Hey, % (n) 
Age, median (range) 
Residence in Southeast Asia 
Recurrent Hey hepatitis post-Tx 
Rejectionc episodes before 
recurrenced (mean) 
Incidence of rejectionc 
Percent of patients receiving 
boluses/mean no. of steroid 
boluses 
Percent of patients receiving 
steroid recycles/mean no. of 
steroid recycles 
Mortality 
Genotype la 
(n=31) 
66% (3/147) 
45 (36-63) 
55% (14131) 
52% (16/31) 
0.54 
31% 
54%/1 
23%/0.46 
45% (14131) 
HCV 
Genotype Ib 
(n=12) 
25% (12147) 
45 (31-54) 
58% (7/12) 
67% (8/12) 
1.1 
57% 
57%/0.71 
14%/0.14 
58% (7/12) 
Genotype 2b 
(n=4) 
9% (4147) 
55 (47-S4) 
25% (1I4) 
25% (114) 
25% (114) 
p 
O.Ola 
NSb 
NS 
NS 
NS 
NS 
NS 
NA 
a Patients with genotype 2b were significantly older than other patients. 
b NS, not significant, P>0.05. 
C Rejection episodes refer to biopsy-proven rejection. 
d Mean values for rejection and immunosuppression are not given for genotype 2b because only one patient in this group developed 
recurrence. 
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FIGURE 1. This Kaplan-Meier curve depicting the probability of re-
current HCY hepatitis in patients with three Hey genotypes; the 
rate of recurrence did not differ significantly among the three 
genotypes. 
TABLE 2. Incidence, timing, and severity of HCY recurrence in 
patients with three HCY genotypesa 
Variable Genotype la Genotype Ib Genotype 2b 
Rate of recurrence 52% (16/3ll 67% (8112) 25% (1/4) 
Time to recurrence, 301 (87-994) 198 (72-174) 111 
median (range) in 
days 
Mean AST level (rulL) 116 88 150 
Mean ALT level (rulL) 124 87 224 
Mean Modell score 5.0 5.8 2 
a None of the variables differed significantly among the three 
genotypes. 
beyond 6 months (median. 14 months: range, 8-48 months). 
. At current follow-up, 48% (5/12) of the patients wi.th type 1a 
and 50% (3/6) of the patients wi.th type 1b were responders. 
Infections. Major infections after transplantation were ob-
served in 48% of the patients with genotype 1a. 75% of the 
patients with type 1b (P=O.ll), and 50% of those wi.th type 
2b. The number of infections per patient, the rate of major 
bacterial infections, major fungal infections, CMV infections, 
and CMV disease did not differ significantly among the three 
genotypes. Likewi.se, when infectious complications were an-
alyzed only in patients with recurrent HCV hepatitis (i.e., 
patients wi.th genotype 1a versus those wi.th genotype 1b), 
the incidences of infections (50% vs. 75%, respectively), major 
bacterial infections (38% vs. 62%), major fungal infections 
(19% vs. 0%), CMV infection (50% vs. 62%), and CMV disease 
(31% vs. 25%) were not significantly different (P>0.20 for all 
infections) (Table 3). 
Mortality. Overall mortality was 16% (5/31) in patients 
with genotype la, 42% (5/12) in patients wi.th genotype 1b, 
and 50% (214) in patients wi.th type 2b (P=NS). Death was 
attributable to recurrent HCV hepatitis in 20% (1/5) of the 
patients wi.th genotype la, 40% (2/5) of the patients wi.th 
genotype 1b, and 0% (0/2) of those with type 2b. When com-
pared with non-HCV patients, actuarial survival for patients 
with and wi.thout HCV recurrence was not significantly dif-
ferent at 12, 24, 36. and 48 months after transplantation. 
Survival at 5 years was lower but not significantly different 
for patients wi.th HCV recurrence (72%) when compared wi.th 
those wi.thout recurrence (77%) and non-HCV patients (84%) 
(P=NS). 
DISCUSSION 
HCV genotype has been shown to be an important predic-
tor of the severity of liver disease independent of the level of 
HCV viremia. These data suggest that HeV genotypes may 
differ intrinsically wi.th respect to virulence. In the nontrans-
plant setting, it has been observed that genotype 1b is asso-
ciated wi.th greater severity of liver disease as well as non-
responsiveness to interferon-a therapy (14-22). In French 
liver transplant recipients, genotype 1b was the predominant 
genotype, occurring in 68% of the patients. Acute and chronic 
recurrent HCV hepatitis was observed in 77% and 59% of the 
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TABLE 3. Major infections in patients with the three Hey 
genotypes 
Genotype Genotype Genotype 
la Ib 2b 
Infections in the study 
population (n=47) 
No. of patients 31 12 4 
Any major infectionQ 48% 75% 50% 
Mean no. of infections 1.0 1.67 1.0 
Major bacterial infections 39% 58% 50% 
Major fungal infections 13% 8% 0 
CMV infection 35% 50% 50% 
CMV disease 16% 25% 25% 
Infections in patients with 
recurrent HCY 
hepatitiso (n=25) 
No. of patients 16 8 1 
Any major infection 50% 75% 
Major bacterial infection 38% 62% 
Major fungal infection 19% 0 
CMV infection 50% 62% 
CMV disease 31% 25% 
a The incidence of infections in the study population and in pa-
tients with recurrent HCY hepatitis only did not differ significantly 
among the genotypes; however, HCY patients with genotype 1b had 
a trend toward a higher incidence of major infection as compared 
with patients with genotype 1a (P=O.l1l. 
b Data presented for genotypes la and 1b because only one patient 
with genotype 2b had HCV recurrence. 
patients, respectively, after 3 years, as compared with only 
40% and 22% in patients with other genotypes (5). Genotype 
1b was also the most prevalent genotype in liver transplant 
recipients in the United Kingdom and was associated with 
more severe allograft injury because of HCV recurrence as 
compared with the other genotypes (7). In contrast, Zhou et 
al. (6) did not observe a significant difference in the incidence 
or severity of posttransplant recurrent hepatitis according to 
genotype; the predominant genotype in this U.S. study was 
also type lb. 
We studied a unique group of patients (U.S. veterans) with 
a high incidence of end-stage liver disease due to HCV hep-
atitis. Since nearly half (23/47) of our study patients with 
HCV had served in Southeast Asia, we hypothesized that we 
would observe a high prevalence of genotypes known to be 
endemic in Southeast Asia and Japan (types lb, 2a, and 2b). 
Surprisingly. 66% of our patients were infected with type la, 
a genotype not endemic in Southeast Asia. Twenty-five per-
cent of our patients had type 1b and only 9% had type 2b. 
This suggests that our patients likely either had HCV infec-
tion before their service or acquired it in the U.S. afterward. 
In contrast to the findings of the European studies, his-
topathologic recurrence was not higher in our patients with 
type lb. Likewise, the time to recurrence or severity of re-
currence as assessed by aminotransferase levels and Knodell 
scores was not significantly greater in patients with genotype 
lb. 
The intensity of immunosuppression has been shown to 
correlate with recurrent HeV hepatitis after liver transplan-
tation (8, 11 J. As the HeV genome undergoes mutation dur-
ing HeV infection, it is conceivable that the different geno-
types interact differently with the host immune response. 
Differences in rate or severity of HCV recurrence among the 
~hree ~enotypes in our study could not be explained by the 
mtenslty of immunosuppression, since the number of rejec-
tion episodes and the cumulative immunosuppression did not 
differ significantly among genotypes. To our knowledge, no 
previous study has assessed immunosuppression as a con-
tributory variable to differences in severity of recurrence 
among various genotypes. 
Patients with recurrent HCV hepatitis have been shown to 
be susceptible to late-occurring infections after transplanta-
tion. Indeed, a recent study in the nontransplant setting 
showed that T cell-derived cytokines were significantly ele-
vated in patients with HCV as compared with nonnal control 
subjects (29). Whether cytokine levels and the infectious 
morbidity varies among genotypes, however, is not known. 
We observed a trend toward a higher incidence of major 
infections in patients with genotype 1b (75%) as compared 
with genotype 1a (48%), although statistical significance was 
not attained (P=O.ll). Patients with genotype 1b or 2b had a 
trend toward higher mortality (42% and 50%, respectively) as 
compared with patients with genotype la (16%, P=O.ll). 
Notably, fungal infections and bacteremias and not overt 
graft failure due to recurrent HCV was the predominant 
cause of death in these patients. 
A number of studies have shown that genotype Ib is nota-
bly refractory to interferon-a therapy in nontransplant pa-
tients (14-16). Other virologic parameters, such as viral RNA 
levels and anti-core IgM HCV antibodies titers, also have 
been shown to be important predictors of response to inter-
feron-a (17-22). Quantitative HCV RNA levels were not 
available for all of our study patients; however, this would 
likely not have altered our conclusions, since HCV genotype 
has been shown to be a predictor of response to interferon-a 
independent ofHCV RNA levels. Although our numbers were 
small, the response rate to interferon-a did not differ signif-
icantly among the genotypes; at 6 months of therapy, 25% of 
the patients with genotype 1a and 17% of patients with type 
1b were responders. With long-term maintenance interfer-
on-a therapy, 48% of the patients with genotype la and 50% 
of the patients with genotype Ib had completely nonnalized 
their aminotransferase levels. A Japanese study in nontrans-
plant HCV patients has also shown that prolonged (up to 52 
weeks) interferon-a therapy appears to suppress relapse af-
ter cessation of therapy (19). We have previously reported 
that long-term therapy with interferon-a for posttransplant 
recurrent HCV is well tolerated and did not appear to pre-
cipitate rejection (30), 
In summary, in the U.S. veterans we studied undergoing 
liver transplantation for end-stage liver disease due to 
HeV hepatitis, genotype la was the predominant geno-
type. Although there was a trend toward greater infectious 
morbidity and higher overall mortality in HCV patients 
infected with genotype lb, the rate of recurrent HCV hep-
atitis, timing to posttransplant recurrence, severity of re-
currence, and response to interferon-a therapy did not 
differ among genotypes. However, we caution that because 
of our small sample size, our findings should be validated 
in other larger studies. Nevertheless, our preliminary ob-
servations suggest that HCV genotype may not be a sig-
nificant factor influencing the posttransplant course of 
U.S. patients with HCV hepatitis. 
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